Inge Marie Svane

National Center for Cancer Immune Therapy, University Hospital Herlev

Affiliated withUniversity Hospital Herlev

Research Area

Immunology and Infection

Biography

Inge Marie Svane has not added Biography.
If you are Inge Marie Svane and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title Cited by 3	2021

Other Publications

Article	Year
Studies on mRNA electroporation of immature and mature dendritic cells: effects on their immunogenic potential. Molecular biotechnology\| PubMed ID: 18543130	2008
CD8 T-cell responses against cyclin B1 in breast cancer patients with tumors overexpressing p53. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 19223507	2009
High immunogenic potential of p53 mRNA-transfected dendritic cells in patients with primary breast cancer. Breast cancer research and treatment\| PubMed ID: 20336365	2011
Identification of a cyclin B1-derived CTL epitope eliciting spontaneous responses in both cancer patients and healthy donors. Cancer immunology, immunotherapy : CII\| PubMed ID: 20981424	2011
Characterization of ex vivo expanded tumor infiltrating lymphocytes from patients with malignant melanoma for clinical application. Journal of skin cancer\| PubMed ID: 21773037	2011
Immunotherapy for metastatic colorectal cancer: present status and new options. Scandinavian journal of gastroenterology\| PubMed ID: 22214467	2012
Tumor associated antigen specific T-cell populations identified in ex vivo expanded TIL cultures. Cellular immunology\| PubMed ID: 22230732	2012
Generation of autologous tumor-specific T cells for adoptive transfer based on vaccination, in vitro restimulation and CD3/CD28 dynabead-induced T cell expansion. Cancer immunology, immunotherapy : CII\| PubMed ID: 22237888	2012
Dissection of T-cell antigen specificity in human melanoma. Cancer research\| PubMed ID: 22311675	2012
FDG PET scans as evaluation of clinical response to dendritic cell vaccination in patients with malignant melanoma. Cancer immunology, immunotherapy : CII\| PubMed ID: 22722450	2013
Characterization of T-cell responses against IκBα in cancer patients. Oncoimmunology\| PubMed ID: 23243592	2012
Analysis of survivin-specific T cells in breast cancer patients using human DCs engineered with survivin mRNA. Methods in molecular biology (Clifton, N.J.)\| PubMed ID: 23296940	2013
Silencing of the glucocorticoid-induced leucine zipper improves the immunogenicity of clinical-grade dendritic cells. Cytotherapy\| PubMed ID: 23643305	2013
The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4 T cells. Oncoimmunology\| PubMed ID: 23734334	2013
Broadening the repertoire of melanoma-associated T-cell epitopes. Cancer immunology, immunotherapy : CII\| PubMed ID: 25854582	2015
Tryptophan 2,3-dioxygenase (TDO)-reactive T cells differ in their functional characteristics in health and cancer. Oncoimmunology\| PubMed ID: 25949861	2015
Indoleamine 2,3-dioxygenase vaccination. Oncoimmunology\| PubMed ID: 25949864	2015
Spontaneous presence of FOXO3-specific T cells in cancer patients. Oncoimmunology\| PubMed ID: 25960934	2014
Reorienting the immune system in the treatment of cancer by using anti-PD-1 and anti-PD-L1 antibodies. Drug discovery today\| PubMed ID: 26189934	2015
Tumor-infiltrating lymphocytes for the treatment of metastatic cancer. Molecular oncology\| PubMed ID: 26578452	2015
Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 27006492	2016
Immune Monitoring Using mRNA-Transfected Dendritic Cells. Methods in molecular biology (Clifton, N.J.)\| PubMed ID: 27236804	2016
Transfection of Tumor-Infiltrating T Cells with mRNA Encoding CXCR2. Methods in molecular biology (Clifton, N.J.)\| PubMed ID: 27236805	2016
Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumab. Cytotherapy\| PubMed ID: 27378345	2016
Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: A randomized phase II study. Cytotherapy\| PubMed ID: 28215654	2017
Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling. Cancer research\| PubMed ID: 28655789	2017
PD-1 Polyfunctional T Cells Dominate the Periphery after Tumor-Infiltrating Lymphocyte Therapy for Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 28679768	2017
Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma. Nature communications\| PubMed ID: 29170503	2017
Checkpoint inhibitors in breast cancer - Current status. Cancer treatment reviews\| PubMed ID: 29287242	2018
T-cell Responses in the Microenvironment of Primary Renal Cell Carcinoma-Implications for Adoptive Cell Therapy. Cancer immunology research\| PubMed ID: 29301752	2018
The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy. Oncoimmunology\| PubMed ID: 29308318	2018
Frequent adaptive immune responses against arginase-1. Oncoimmunology\| PubMed ID: 29399404	2018
Cancer immunotherapy in patients with brain metastases. Cancer immunology, immunotherapy : CII\| PubMed ID: 29520474	2018
[Cancer immunotherapy]. Ugeskrift for laeger\| PubMed ID: 29804567	2018
Spontaneous T-cell responses against the immune check point programmed-death-ligand 1 (PD-L1) in patients with chronic myeloproliferative neoplasms correlate with disease stage and clinical ... Oncoimmunology\| PubMed ID: 29872567	2018
The real-world impact of modern treatments on the survival of patients with metastatic melanoma. European journal of cancer (Oxford, England : 1990)\| PubMed ID: 30605822	2019
Tumour-reactive T cell subsets in the microenvironment of ovarian cancer. British journal of cancer\| PubMed ID: 30718808	2019
Collagen density regulates the activity of tumor-infiltrating T cells. Journal for immunotherapy of cancer\| PubMed ID: 30867051	2019
Correction: Tumour-reactive T cell subsets in the microenvironment of ovarian cancer. British journal of cancer\| PubMed ID: 30890776	2019
MERTK Acts as a Costimulatory Receptor on Human CD8 T Cells. Cancer immunology research\| PubMed ID: 31266785	2019
Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma. Cancers\| PubMed ID: 31623302	2019
Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitope. Cancer immunology, immunotherapy : CII\| PubMed ID: 31690955	2019
Long-Term Exposure to Inflammation Induces Differential Cytokine Patterns and Apoptosis in Dendritic Cells. Frontiers in immunology\| PubMed ID: 31824496	2019
CTLA-4 blockade boosts the expansion of tumor-reactive CD8 tumor-infiltrating lymphocytes in ovarian cancer. Scientific reports\| PubMed ID: 32127601	2020
Author Correction: Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma. Nature communications\| PubMed ID: 32238805	2020
In vitro 4-1BB stimulation promotes expansion of CD8 tumor-infiltrating lymphocytes from various sarcoma subtypes. Cancer immunology, immunotherapy : CII\| PubMed ID: 32472369	2020
T-Cell Gene Therapy in Cancer Immunotherapy: Why It Is No Longer Just CARs on The Road. Cells\| PubMed ID: 32630096	2020
Escape from nonsense-mediated decay associates with anti-tumor immunogenicity. Nature communications\| PubMed ID: 32733040	2020
Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma. Journal for immunotherapy of cancer\| PubMed ID: 32747469	2020
The metabolic enzyme arginase-2 is a potential target for novel immune modulatory vaccines. Oncoimmunology\| PubMed ID: 32923127	2020
The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study. European heart journal\| PubMed ID: 33291147	2021
The capacity of CD4 Vγ9Vδ2 T cells to kill cancer cells correlates with co-expression of CD56. Cytotherapy\| PubMed ID: 33785258	2021
Immune Cell Profiling of Peripheral Blood as Signature for Response During Checkpoint Inhibition Across Cancer Types. Frontiers in oncology\| PubMed ID: 33842304	2021
Bone marrow toxicity and immune reconstitution in melanoma and non-melanoma solid cancer patients after non-myeloablative conditioning with chemotherapy and checkpoint inhibition. Cytotherapy\| PubMed ID: 33933372	2021
Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanoma. Journal for immunotherapy of cancer\| PubMed ID: 34210820	2021
Lynch syndrome-associated epithelial ovarian cancer and its immunological profile. Gynecologic oncology\| PubMed ID: 34275654	2021
Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types. Journal for immunotherapy of cancer\| PubMed ID: 34607899	2021